Algorae Pharmaceuticals (ASX:1AI) has taken another step in its push to transform drug discovery through artificial intelligence, deepening its collaboration with the Peter MacCallum Cancer Centre in a new program aimed at validating AI-predicted drug combinations.
The agreement brings Algorae back together with the Victorian Centre for Functional Genomics, a specialist unit within Peter Mac, to test a carefully selected group of drug pairs identified by the company’s proprietary platform, AlgoraeOS version 2.
The initiative reflects a growing effort to bridge the gap between computational prediction and biological reality, a critical hurdle in modern pharmaceutical development.
At the heart of the project is a shortlist of twenty-four high-priority drug combinations. These candidates were drawn from a much larger pool of ninety possibilities, themselves distilled from an expansive dataset of more than half a million potential interactions involving cannabidiol and thousands of approved or investigational drugs. The selections were made using criteria that balanced predicted effectiveness, uncertainty, and biological relevance, alongside commercial and intellectual property considerations.
The validation process will take place across four cancer types, including glioblastoma, rhabdomyosarcoma, melanoma and chronic myelogenous leukaemia. Using high-throughput screening technologies, researchers will examine how these drug combinations interact in cancer cell lines and determine whether the predicted synergies translate into real therapeutic potential.
For Algorae, the program represents a key milestone in demonstrating that its AI-driven system can reliably identify meaningful drug interactions. The company’s Chief Scientific Officer framed the collaboration as an important step in connecting digital prediction with biological validation, a transition that ultimately determines whether AI can deliver practical value in medicine.
The underlying platform, AlgoraeOS, has been developed in collaboration with the UNSW AI Institute and supported by national research funding. Its latest iteration is designed not only to predict whether drugs will work together, but also to quantify the confidence of those predictions. By incorporating measures of uncertainty, the system enables more informed decision-making about which candidates should move forward into costly and time-consuming experimental phases.
The screening program has been structured to generate results efficiently while maintaining scientific rigour. It will include optimisation of cell growth conditions, detailed measurement of treatment effects, and the construction of dose response profiles for individual drugs before combinations are tested. Data from each screening run will be analysed within weeks, with the full dataset expected within six months.
Positive validation would not strengthen confidence in the identified drug combinations and open pathways for clinical development, licensing deals, or broader partnerships within the pharmaceutical industry. It could also support the expansion of the AI platform into new therapeutic areas beyond oncology.
The collaboration highlights a broader trend in healthcare: artificial intelligence is increasingly integrated into the earliest stages of drug discovery. By narrowing vast possibilities into a manageable set of high-probability candidates, companies like Algorae aim to reduce both the time and cost of bringing new treatments to patients.
At Peter Mac, a centre that treats tens of thousands of cancer patients each year while maintaining a strong research focus, the partnership aligns with its mission to combine cutting-edge science with clinical impact. The involvement of the Victorian Centre for Functional Genomics adds a layer of technical expertise in high-throughput screening and advanced analytics, ensuring that the experimental validation is as robust as the computational predictions that preceded it.